Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.
1. A composition for subcutaneous administration comprising an antibody in high concentration formulation buffer, wherein the antibody or immunoglobulin is concentrated to at least 225 mg/ml, wherein the buffer is pH 4.5 to 5.5 and comprises 6.2 mM citric acid monohydrate, 105 mM sodium chloride, 1.2 mM sodium citrate dihydrate, 8.7 mM sodium phosphate dibasic, 5.5 mM sodium phosphate monobasic, 0.1% polysorbate 80 and 66 mM mannitol, wherein the antibody is a chimeric, humanized or human antibody.
2. The composition of claim 1 , wherein the antibody has a glutamate at Kabat residue 356 and methionine at Kabat residue 358 of the antibody heavy chain.
3. The composition of claim 1 , wherein the high concentration formulation buffer further comprises arginine and glutamic acid.
4. The composition of claim 1 , wherein the antibody has an arginine at Kabat position 214 of the antibody heavy chain.
5. The composition of claim 1 , wherein the antibody has a glutamate at Kabat position 356, methionine at Kabat position 358 and alanine at Kabat position 431 of the antibody heavy chain.
6. The composition of claim 1 , wherein the antibody has a valine at Kabat position 153 and leucine at Kabat position 191 of the antibody light chain.
7. The composition of claim 1 , wherein the antibody comprises heavy chain constant region amino acid residues arginine-214, glutamic acid-356, methionine-358 and alanine-11.
8. The composition of claim 1 , wherein the antibody is a naked antibody.
9. The composition of claim 1 , wherein the antibody is conjugated to at least one non-cytotoxic therapeutic or diagnostic agent.
10. The composition of claim 9 , wherein the therapeutic agent is selected from the group consisting of an antibody, an antibody fragment, an immunomodulator, a cytokine, a chemokine, a tyrosine kinase inhibitor, a growth factor, a stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor (CSF), an interleukin (IL), an interferon (IFN), a hormone and an enzyme.
11. The composition of claim 10 , wherein the therapeutic agent is selected from the group consisting of erythropoietin, thrombopoietin tumor necrosis factor-α (TNF), TNF-β, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), interferon-α, interferon-β, interferon-γ, stem cell growth factor designated “S1 factor”, human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, NGF-β, platelet-growth factor, TGF-α, TGF-β, insulin-like growth factor-I, insulin-like growth factor-II, macrophage-CSF (M-CSF), IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-23, IL-25, LIF, FLT-3, angiostatin, thrombospondin, endostatin and lymphotoxin.
12. The composition of claim 1 , wherein the antibody binds to an antigen selected from the group consisting of carbonic anhydrase IX, CCL19, CCL21, CSAp, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, IGF-1R, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a-e, CD67, CD70, CD70L, CD74, CD79a, CD80, CD83, CD95, CD126, CD132, CD133, CD138, CD147, CD154, AFP, PSMA, CEACAM5, CEACAM6, B7, ED-B of fibronectin, Factor H, FHL-1, Flt-3, folate receptor, GRO-β, HMGB-1, hypoxia inducible factor (HIF), HM1.24, insulin-like growth factor-1 (ILGF-1), IFN-γ, IFN-α, IFN-β, IL-2, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5, PAM4 antigen, NCA-95, NCA-90, Ia, HM1.24, EGP-1, EGP-2, HLA-DR, tenascin, Le(y), RANTES, T101, TAC, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, TNF-α, TRAIL receptor (R1 and R2), VEGFR, EGFR, P1GF, complement factors C3, C3a, C3b, C5a, C5, and an oncogene product.
13. The composition of claim 1 , wherein the antibody is selected from the group consisting of hR1 (anti-IGF-1R), hPAM4 (anti-mucin), hA20 (anti-CD20), GA101 (anti-CD20), hA19 (anti-CD19), hIMMU31 (anti-AFP), hLL1 (anti-CD74), hLL2 (anti-CD22), hMu-9 (anti-CSAp), hL243 (anti-HLA-DR), hL243 IgG4P (anti-HLA-DR), hMN-14 (anti-CEACAM5), hMN-15 (anti-CEACAM6), hRS7 (anti-EGP-1), hMN-3 (anti-CEACAM6), hRFB4 (anti-CD22), Ab124 (anti-CXCR4) and Ab125 (anti-CXCR4).
14. The composition of claim 1 , wherein the antibody is selected from the group consisting of epratuzumab, veltuzumab, milatuzumab, hL243 (anti-HLA-DR) and hL243 IgG4P (anti-HLA-DR).
15. The composition of claim 1 , wherein the antibody is epratuzumab.
16. The composition of claim 1 , wherein the antibody is veltuzumab.
17. The composition of claim 1 , wherein the antibody is milatuzumab.
18. The composition of claim 1 , wherein the antibody is clivatuzumab.
19. The composition of claim 1 , wherein the antibody is labetuzumab.
20. The composition of claim 1 , wherein the antibody is hL243.
21. The composition of claim 1 , wherein the antibody is a bispecific antibody.
22. The composition of claim 20 , wherein the bispecific antibody binds to two different antigens, each antigen selected from the group consisting of CD19, CD20, CD22, CD74, CD79a, CD40L, ILGF-R1, TROP2, CEACAM5, CEACAM6, HLA-DR, IFNα, IL-6 and TNF-α.
23. The composition of claim 1 , wherein the antibody concentration is at least 250, at least 275 or at least 300 mg/ml.